|
|
 |
|
Viewing report
|
|
|
|
Global Osteoporosis Market & Drugs Analysis 2010 – 2015
Renub Research, Sep 2011, Pages: 72
Osteoporosis Market Overview:
Osteoporosis is often called the ''silent disease'' because bone loss occurs without symptoms. It is characterized by low bone mass and micro-architectural deterioration of bone tissue, leading to bone fragility and a consequent increase in risk of fracture. Global osteoporosis market is expected to reach 16 Billion by 2015. This significant growth is primarily attributed to strong treatment options currently available in the market as well as strong pipeline products. The increase in the prevalence of osteoporosis among the female population is the principal driver of the osteoporosis market and will continue to be in the future.
Fosamax was the undisputed leading product in the history of global osteoporosis drug market till 2007. It has a market share of nearly 37% in 2007 but, declined to 5% by 2015 due to patent expiry and competition from cheaper generics. Boniva and Evista were leading the osteoporosis market till 2010 but the dynamics of osteoporosis market is expected to change by 2011 as Prolia is going to be introduced in the market. It is predicted that Prolia will lead the market with nearly 45% share by 2015.
The osteoporosis market offers multiple opportunities for current and future market players. In addition to increasing awareness, diagnosis and treatment, there is the need to develop new drugs that promote bone building. While the market awaits new growth, driven by the launch of several promising pipeline drugs, including Amgen’s Prolia (denosumab), companies are looking for innovative ways to maximize revenues from their products nearing the end of their lifecycles.
Report Details
Global Osteoporosis Market & Drugs Analysis 2010 – 2015” report provides an in-depth analysis of the past, present and future prospects. The report has been researched at source globally and features latest available data covering:
- Global Osteoporosis Market (2009 to 2015)
- Four Osteoporosis Drug Class (Bisphosphonate, SERM, PTH and Calcitonin) market and market share data of (2006 to 2014)
- Top Nine Osteoporosis Drug Brand (Fosamax, Actonel, Reclast, Boniva, Evista, Forteo, Viviant/Conbriza, Miacalcin, Prolia) sales and market share data of 2007 to 2015
- Six Countries (USA, European Union, Japan, China, India, Korea) Osteoporosis market share data of (2009 to 2015)
- Six Countries (USA, European Union, Japan, China, India, Korea) Osteoporosis market data of (2005 to 2015)
- Pipeline Developmental Agents (Odanacatib, Aprela) Future Trends
- Key Companies (Eli Lilly, Roche, Amgen, Merck & Novartis) Analysis – Revenue in Osteoporosis Market (2007 to 2010), Strength & Weakness in Osteoporosis Market
Research Highlights
- Global Osteoporosis drug market is expected to reach the figure of US$ 16 Billion by 2015
- United States Osteoporosis drug market was nearly US$ 5 Billion in 2010
- United States & China together is expected to control 61% market share in osteoporosis drug market by 2015
- Although SERM is increasing its market share year on year but Bisphosphonates will continue to dominate the osteoporosis drug class segment with 56% in 2014
- Prolia will lead the Osteoporosis drug market with 45% share by 2015
Data Sources
Information and data in this report has been collected from various printable and non-printable sources like Trade Journals, White papers, News websites, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 100 paid databases.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
